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Abstract Objective: Otologic methicillin-resistant Staphylococcus aureus (MRSA) infection has
historically been rare, but given the rise in community-acquired MRSA carriage and infection at
other body sites, prevalence rates may be changing. The goal of this study was to determine
the prevalence of MRSA in recent otologic cultures from patients with acute otitis externa (AOE).
Study design: Retrospective review of an institutional microbiologic database.
Methods: A retrospective analysiswas performedon serial culture isolates taken from theear at a
quaternary care hospital from January 2014 to April 2016. The causative pathogen and antibiotic
sensitivitywas determined by culture isolation and end pointmean inhibitory concentration (MIC)
testing. Medical records were reviewed to document patient characteristics, chronicity of infec-
tion, symptomatology, and previous treatments.
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Results: Over the study period, 173 patients were diagnosed with AOE and underwent otologic
cultures of the ear. Fifty-three (30.6%) of cultures grew S. aureus (SA). Of SA infections, 15
(28.3%) were identified as MRSA. MRSA patients were typically older than patients with
methicillin-sensitive SA (MSSA) (mean age 46.7 17.9 vs 29 19.4, PZ 0.003) and hadmoremed-
ical comorbidities (4 vs 1.7, PZ 0.001). Compared to patientswithMSSA, patientswithMRSAwere
significantly more likely to have had prior ototopical antibiotic exposure (37% vs 73%, PZ 0.019).
Conclusion: Contemporary ear culture isolates at quaternary care center show higher rates of
MRSA compared to historical reports in the literature. Clinicians should consider ear cultures to
identify MRSA AOE.
Level of Evidence: IV.
Copyright ª 2017 Chinese Medical Association. Production and hosting by Elsevier B.V. on behalf
of KeAi Communications Co., Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Acute otitis externa (AOE) is a common otologic condition,
affecting 1 of every 10 individuals.1 Defined as an infection
of the skin and soft tissue of the external auditory canal,
AOE can be caused by a variety of bacteria or fungi. While
most symptoms of AOE are mild, complications of AOE may
be serious, including necrotizing infection, facial nerve
paralysis, osteomyelitis, and rarely death.1
The implicated pathogens in acute bacterial otitis
externa vary geographically, but most commonly involve
Pseudomonas and Staphylococcus aureus.1 Pseudomonas
species are estimated to be responsible for 20%e71.3% of
cases.2,3 S. aureus is thought to be the second most com-
mon pathogen in acute bacterial otitis externa, with case
series identifying S. aureus in up to 40% of cases.3e13
Studies from Pakistan, Korea and New Zealand found
rates of S. aureus AOE above 30%,10e12 while the most
recent study in the U.S. reported rates of 7.8%.3
Current guidelines for treatment of otitis externa focus
on Pseudomonas spp. and S. aureus because of their high
incidence in AOE. Generally, empiric management with
topical antibiotics targeting non-resistant strains of these
bacteria is recommended.2 A 2014 update of the clinical
practice guidelines (American Academy of Otolaryngology-
Head and Neck Surgery [AAO-HNS]2) identifies topical fluo-
roquinolones, aminoglycosides, and/or polymyxin B for
empiric treatment. While most systematic reviews have
found no significant difference in treatment outcomes with
antiseptic or different types of antibiotic drops treating
AOE, two meta analyses by Rosenfeld et al14 and Mo¨sgen
et al15 suggest that quinolone drops resulted in higher rates
of bacteriologic and clinical cure e defined as the absence
of pathogen on follow up and resolution of clinical symp-
toms. At present, empiric treatment with ototopical anti-
biotic drops is recommended, unless there is extension of
infection outside the ear canal, or the patient has con-
cerning host factors such as immunocompromise or dia-
betes. In such cases, the inclusion of systemic antibiotics is
appropriate.
While sensitive S. aureus may be treated similarly to
other gram positive bacteria, methicillin-resistant S. aureus
(MRSA) otitis externa, represents a greater therapeutic
challenge.16 Since their initial detection in the 1960’s,
MRSA infections in the U.S. have been typically associated
mainly with hospitalized patients.17 MRSA represents a
significant healthcare burden worldwide, as patients with
MRSA have more difficult-to-treat infections, associated
with longer hospital stays, and a much higher cost-of-
care.18 Another risk factor for MRSA is recent exposure to
antibiotics, especially quinolones.19,20
While MRSA remained mainly nosocomial in nature
through the 1980’s, community-acquired MRSA (CA-MRSA)
emerged in the 1990’s and has become increasingly com-
mon in soft tissue and otolaryngologic infections
since.16,21,22 In 2002, Hwang et al16 reported >8.5% in-
crease in CA-MRSA incidence in otologic infections in
Taiwan. Similarly, in 2007 a group from Hawaii21 noted a
rapid increase in CA-MRSA head and neck infections from
21% to 64% over a five-year period.
Despite the rise of MRSA soft tissue infections, few
studies have examined contemporary clinical features and
incidence patterns of MRSA in AOE. In the UK, an English
2007 study and an Irish 2001 study have reported rates of
0.7% and 6%, respectively.6,7 The most recently published
work on uncomplicated AOE, a 2012 study from Singapore,
reported a MRSA AOE rate of 4.2%.13 Studies in South Africa,
Pakistan and Korea found no MRSA in AOE cultures,
consistent with the low levels of MRSA colonization of their
populations.8,10,11
The aim of the current study was to determine
contemporary incidence rates, resistance patterns and
clinical features of MRSA AOE diagnosed and treated at a
quaternary care center in the United States.
Materials and methods
A retrospective chart review was performed on all patients
at a quaternary care center with an available otologic
culture between January 2014 and April 2016. Inclusion
criteria included patients presenting with acute otologic
symptoms who were clinically diagnosed with AOE, and who
underwent an ear culture. Exclusion criteria included pa-
tients presenting with otitis media, chronic otitis externa,
primarily non-otologic symptoms, hospitalized patients,
and post-operative patients. While all patients presented
from the community, some had recent outpatient exposure
to antibiotic agents, and a thorough review of their chart
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included topical antibiotics used in the affected ear over
the preceding 6 months. Other information gathered from
the patient chart included demographics, comorbidities,
symptomatology, physical exam findings, and otologic out-
comes. Comorbidities evaluated included otologic disease
(i.e., chronic otitis, existing hearing aid or other prosthesis)
and systemic disease (with special attention given to dia-
betes, immunocompromise, and malignancy).
Bacterial culture findings and antibiotic resistance pat-
terns on included patients were reviewed. Swabs were
taken from the site of infection and cultured on various
agars, following standard institutional microbiological
analysis protocols. Bacterial identification and antibiotic
susceptibility testing were performed using the MicroScan
WalkAway 40 Plus System (Beckman Coulter).
Statistical analysis of the collected data was performed
using Stata statistical software (StataCorp, 2015). Pearson’s
c2 test and unpaired t-tests were performed to determine
significant associations in the microbial patterns and pa-
tient data. A P value of <0.05 was considered statistically
significant. This study was approved by the Human Subjects
Committee of our Institutional Review Board (Protocol
#914379).
Results
Patient demographics
From 2014 to 2016, 179 patients had a clinical diagnosis of
AOE and available culture data supporting the diagnosis of a
bacterial infection. Six patients with concomitant chronic
otitis media were excluded from the study. Of the
remaining 173 patients, 45.7% (79/173) were male. The
mean age was 34.2  23.8. Adult patients (defined as pa-
tients >18 years old) comprised 66% of the study
population.
Bacterial isolates in otitis externa
Of the 173 patients, 73 (42.2%) yielded Pseudomonas aer-
uginosa as the primary pathogen identified. S. aureus was
the second most commonly isolated pathogen (53/173,
30.6%). Of the 53 S. aureus isolates, 38 (71.7%) were
methicillin-sensitive S. aureus (MSSA) and 15 (28.3%) were
methicillin-resistant S. aureus (MRSA). Thus, 22.0% (38/173)
of all AOE patients analyzed were infected with MSSA, and
8.7% (15/173) with MRSA. The next most common species
isolated from AOE cases was Enterococcus faecalis (5.2%).
Escherichia coli, Stenotrophomonas maltophilia, and
Streptococcus pneumoniae each were isolated from 2.3% of
patients (Table 1).
Comparison of demographics and symptomatology
of MSSA and P. aeruginosa AOE versus MRSA AOE
The average age of the 38 patients with MSSA was
29.0  19.4 (range 5e74), and 13/38 (34%) were pediatric
patients. The average age for the 73 patients with P. aer-
uginosa was 31.2  22.7 (range 1e90), and 28/73 (38%)
were pediatric patients. In contrast, the average age of
patients with MRSA was 47.7  17.9 (range 13e68), and
included only one pediatric patient. Of patients with MSSA,
36% were male (Table 2), whereas there was a slight male
predominance (54%) among MRSA AOE cases.
The average number of comorbidities (defined as sys-
temic chronic conditions at the time of culture) for AOE
associated with MRSA was 4 (range 0e12), which was
significantly higher than for MSSA patients at 0.8 (range
0e3), P < 0.01 and P. aeruginosa patients at 1 (range 0e2),
P < 0.01. Of 15 AOE patients with MRSA, one was diabetic
and two were immunocompromised. No patient with MSSA
had either diabetes or was immunocompromised.
All three groups of AOE patients presented with similar
symptoms (Table 3). The most common symptoms were
otorrhea, otalgia, swelling, and hearing loss/blocked ear.
Swelling was more common in MRSA associated cases
(33.3%) compared MSSA cases (5.3%, P Z 0.01). and P.
aeruginosa cases (19.2%, P Z 0.2). Patients with Pseudo-
monas were more likely to present with otalgia than MRSA
patients (83.6% vs 60.0%, P Z 0.04). Data on time to reso-
lution of symptoms was available for only a subset of pa-
tients who had several follow up visits. Mean time to
resolution was calculated from the point in the clinical
history at which the patient reported no longer being
symptomatic. Resolution of symptoms appeared to take
Table 1 Distribution of isolates in patients diagnosed with
acute otitis externa.
Culture isolate n Percentage
of OE (%)
Pseudomonas aeruginosa 73 42.0
Methicillin-sensitive
Staphylococcus aureus
38 22.0
Methicillin-resistant
Staphylococcus aureus
15 8.7
Enterococcus faecalis 9 5.2
Escherichia coli 4 2.3
Stenotrophomonas maltophilia 4 2.3
S. pneumoniae 4 2.3
Coagulase negative
Staphylococcus species
4 2.3
Staphylococcus epidermidis 4 2.3
Serratia marcescens 3 1.7
Achromobacter xylos oxidan 2 1.1
Citrobacter koseri 2 1.1
Acinetobacter
baumannii/haemolyticus
1 0.6
Actinomyces odontolyticus 1 0.6
Alcaligenes species 1 0.6
Enterobacter aerogenes 1 0.6
Enterococcus casseliflavus 1 0.6
Haemophilus influenzae 1 0.6
Klebsiella oxytoca 1 0.6
Proteus mirabilis 1 0.6
Pseudomonas stutzeri 1 0.6
Resembles Aspergillus species 1 0.6
Staphylococcus warneri 1 0.6
Streptococcus group G 1 0.6
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longer in MRSA infected patients (21.5 days) than in pa-
tients with P. aeruginosa (15 days) and patients with MSSA
(11.2 days). The difference in resolution of symptoms was
statistically significant for P. aeruginosa versus MRSA pa-
tients (P Z 0.04). Due the smaller numbers of MSSA pa-
tients included, the difference between MRSA and MSSA
patients did not achieve significance (P Z 0.11).
Antibiotic sensitivities
MRSA isolates were significantly more likely (P < 0.05)
than MSSA isolates to be resistant to multiple antibiotics,
including erythromycin and levofloxacin. Both groups
exhibited high proportions of resistance to amikacin
(Table 4).
A sub-analysis of AOE patients with prior exposure to otic
antibiotic drops (ciprofloxacin, ofloxacin, tobramycin,
neomycin, gentamicin) was performed. Of 53 total patients
infected with S. aureus, 25 (47.1%) had a prior history of
antibiotic otic drops within the past 6 months. Of those
using drops, 11 were infected with MRSA (73.3% of MRSA
isolates) and 14 were infected with MSSA (36.8% of MSSA
isolates, Table 2). The most common exposure was to qui-
nolone drops, in 9 out of 11 previously exposed patients
with MRSA isolates. This was significantly different from
patients with MSSA, in which 8 out 14 previously exposed
patients had been exposed to quinolone drops (PZ 0.019).
Table 2 Demographics presentation, and previous exposure to antibiotic drops of S. aureus acute otitis externa infections.
Nine out of 11 patients with MRSA exposed to otic drops were exposed to quinolone drops.**Significantly different from MRSA.
Group Average age (y) Sex Average number of
comorbidities
Average time to
resolution of
symptoms (days)
Previous exposure
to otic drops
MRSA 46.7 (13e68; 1 pedi patient) 54% M; 46% F 4 (0e12) 21.5 (3e42; data
available
for n Z 6)
11 (73%)
MSSA 29.0 (5e74; 13 pedi patients,
P < 0.01)**
36% M; 64% F 1.7 (0e6,
P < 0.01)**
11.2 (1e42) 14 (37%, P Z 0.019)**
P. aeruginosa 31.2 (1e90; 28 pedi patients,
P Z 0.014)**
46.6% M; 53.4% F 1 (0e2,
P < 0.01)**
15 (2e56,
P Z 0.04)**
35 (48%)
Table 3 Symptoms of S. aureus acute otitis externa infections. *P < 0.05; **Significantly different from MRSA.
Group n Otorrhea
cases (%)
Otalgia cases (%) Swelling* cases (%) Hearing loss cases (%)
MRSA 15 9 (60.0) 9 (60.0) 5 (33.3) 4 (26.7)
MSSA 38 23 (60.5) 19 (50.0) 2 (5.3)**(P < 0.01) 5 (13.2)
P. aeruginosa 73 47 (64.3) 61 (83.6%)**
(P Z 0.04)
14 (19.2) 23 (31.5)
Table 4 Proportion of S. aureus isolates resistant to listed antibiotics. NA: Not applicable. *P < 0.05.
Antibiotic MRSA Number (%)
of specimens
showing resistance
to antibiotic
MSSA Number (%)
of specimens showing
resistance to antibiotic
P value
Amikacin 13 (100) 1 (100) NS
Amoxicillin/Clavulanate NA 22 (100) NA
Ampicillin NA 5 (71.4) NA
Clindamycin 0 (0) 7 (18.4) 0.51
Daptomycin 0 (0) 0 (0) NS
Erythromycin* 12 (80) 9 (25.7) <0.001
Gentamicin 1 (6.67) 0 (0) 0.11
Levofloxacin* 5 (33.3) 2 (5.26) 0.007
Linezolid 0 (0) 0 (0) NA
Penicillin* NA 28 (73.68) NA
Tetracycline 1 (6.67) 2 (5.4) 0.51
Trimethoprim/sulfamethoxazole 1 (6.67) 1 (2.7) 0.86
Vancomycin 0 (0) 0 (0) NA
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Discussion
In the current study, we found S. aureus as the likely
pathogen of AOE in 30.6% of cases, which is higher than
previously reported in the U.S., which found a rate of
7.8%.3 This difference could be reflective of changing
population demographics and/or changes in the nature of
strains of S. aureus occurring in the community. Local
modifications in the external ear microbial population may
also result from the selective pressure imposed by empir-
ical antibiotic treatment. As the likely causative agent of 1
in 3 AOE cases, S. aureus should be factored into antimi-
crobial coverage decisions on initiation of empiric
treatment.
Among patients with S. aureus otitis externa, we iden-
tified MRSA in 8.7% of cases e over three times the last
reported U.S. rate, from 20023 (Table 5). Because the
incidence of MRSA in soft tissue infection is reflective of
carriage rate in the population, understanding our evolving
microbial carriage patterns is critically important. The last
large scale study on the microbiology of AOE in the U.S. by
Roland et al3 was reported over 15 years ago. Our search of
the literature yielded only one other U.S. study examining
the epidemiology of MRSA otitis: a 2014 study from Pitts-
burg Medical Center, which reported an MRSA rate of 15%
among malignant otitis externa cases caused by S. aureus.4
These findings may indicate that MRSA AOE, when not
identified and treated early, may more frequently result in
advanced disease and complications.
While little is known about MRSA in AOE, increasing rates
of MRSA in soft tissue infections21 and in otolaryn-
gology,16,22 are well-documented. The increased incidence
observed in our study, when compared to the earlier find-
ings of Roland et al3 appear to be consistent with the global
trend of increasing prevalence of community-acquired
MRSA carriage18 and infection17,22 over the past 20 years.
In general, we found that MRSA AOE presented with a
spectrum of symptoms similar to infections caused by MSSA,
but was more likely to be associated with significant
(P Z 0.006) ear canal swelling. Rapid onset, severe
swelling, tenderness and erythema have been observed
before in MRSA head and neck infections, and, when
encountered, should raise the index of suspicion of MRSA
otitis for the clinician.22 Patients with MRSA tended to
experience a longer time to resolution of symptoms. MRSA
AOE tended to be associated with diabetes, immunocom-
promise and comorbidities to a greater degree than MSSA.
In fact, the only case of malignant otitis externa among this
cohort was a patient with MRSA AOE. Because of the po-
tential for extended-duration, more severe infection, care
providers should consider MRSA AOE when a patient pre-
sents and fails to improve quickly with empiric treatment.
We also found that patients with MRSA had a higher
exposure to previous ototopical drops than did patients
with MSSA AOE. In fact, 73% of patients with MRSA had been
exposed to otic drops in the past 6 months, and of these,
most had been exposed to quinolone drops. Exposure to
prior ototopical drops may select for resistant organisms,
allowing them to become the primary pathogen during an
episode of AOE. The ophthalmology literature studying the
use of quinolone drops on corneal ulcers has demonstrated
a significant increase in resistant organisms after the use of
fluoroquinolone drops.23 Similarly, a higher level of nasal
MRSA colonization has been found in patients exposed to
fluoroquinolones.24 Other work by Venezia et al20 has shown
a mechanistic link between quinolone usage and selection
for oxacillin-resistant organisms, and concluded that
exposure to fluoroquinolones greatly increases the likeli-
hood of developing MRSA, even in as short a period as 8 h
after exposure. A 2004 meta-analysis of otologic in-
fections,25 concluded that empiric antibiotic drops were
unlikely to be associated with the development of resistant
organisms. However, this study was limited by very small
sample size (2 patients with OE), and is now over 10 years
old. It is possible that the microbiologic landscape has
changed significantly in intervening years. Larger,
contemporary studies in OE should be performed to better
understand the relationship between empiric antibiotic
therapy and the rise in MRSA infections.
Notwithstanding the effects of quinolones in selecting
for MRSA, the fact that in our study almost 1 in 10 patients
with AOE had MRSA highlights the importance of adequate
treatment and close follow up of the disease. MRSA is a
known cause of chronic otitis media (COM) and chronic
otorrhea, and clinical algorithms focused on topical van-
comycin therapy have been developed to guide clinicians in
treating those cases.26 No such algorithm exists for MRSA in
otitis externa. However, clinical guidelines on antibiotic
use in otolaryngology currently recommend using vanco-
mycin drops in ears affected by MRSA,27 and practitioners
should follow this for AOE. At our institution, once external
auditory infection with MRSA is confirmed via culture,
vancomycin drops (25 mg/ml) twice daily or tobramycin
drops (13.6 mg/ml) three times daily for ten days are
Table 5 The prevalence of S. aureus acute otitis externa in this study compared to existing studies.
Year published Location Type of institution Years of data collection MRSA AOE MSSA AOE
Duarte et al 2017 United States Tertiary 2014e2016 8.7% (n Z 15) 22.0% (n Z 38)
Roland et al 2002 United States Various 1998e2000 2.70% (n Z 6) 7.80% (n Z 215)
Roland et al 2007 United Kingdom Tertiary 2006 0.70% (n Z 1) 9% (n Z 13)
Walshe et al 2001 Ireland Primary 2000 6% (n Z 15) 23.80% (n Z 57)
Meyer et al 2013 South Africa Tertiary 2005e2009 0 24% (n Z 5)
Cheong et al 2012 Singapore Tertiary 2010e2011 4.20% (n Z 2) 21% (n Z 16)
Arshad et al 2004 Pakistan Primary 2002e2003 0 38% (n Z 41)
Kim et al 2016 Korea Tertiary 1995, 2000, 2004, 2013 0 36% (n Z 63)
Jayakar et al 2014 New Zealand Various 2007e2011 0 31.90% (n Z 46)
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prescribed, and the patient is followed closely with serial
exams. Based on our institution’s guidelines and the data
available for MRSA COM, we propose a modified clinical
algorithm for AOE that includes consideration of MRSA in-
fections and the implementation of otologic cultures at the
point where the current guidelines recommend re-assessing
patients who are not improving with standard antibiotic
therapy (Fig. 1, modified from the 2014 AAO-HNS clinical
practice guidelines). Given the increasing prevalence of
MRSA in AOE in this study and in otolaryngologic infections
worldwide, robust trials elucidating the optimal topical
antibiotic regimen (vancomycin or otherwise) may be
warranted.
This study is limited to only one geographic region in the
U.S. (New England), and to patients presenting to our
institution who had otologic cultures. While primary cul-
tures are routinely taken on patients presenting to our
institution, this practice is not uniform and cultures were
not obtained on all patients presenting with AOE. Addi-
tionally, many patients with AOE are diagnosed and treated
Fig. 1 Clinical treatment algorithm for otitis externa. In Black: Current treatment algorithm for treating acute otitis externa,
from the 2014 Clinical Practice Guideline on Acute Otitis Externa, published by the American Academy of Otolaryngology and Head
and Neck Surgery. In Blue: Proposed modified AAO-HNS algorithm: if there is no clinical improvement with empiric treatment after
72 h, reassess patient and consider MRSA as a potential source of infection.
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clinically by primary care physicians and do not reach our
institution for culture, follow up and inclusion in this study.
While we focused our analysis on bacterial AOE, and not OE
of a fungal etiology, these patients represented a small
minority of patients with AOE (Table 1). The review was
retrospective, thus some data was incomplete and may be
subject to selection bias. In addition, this study was per-
formed in a quaternary care center, which serves as a
referral site for community physicians. It is possible that
patients were exposed to unknown antibiotic treatment
before presentation, and that follow up with community
physicians inadequately captured the patient’s entire
course of disease.
Conclusion
Contemporary ear culture isolates at quaternary care cen-
ter show higher rates of MRSA compared to historical re-
ports in the literature. Clinicians should consider ear
cultures to identify MRSA AOE.
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